X4 Pharmaceuticals (XFOR) Share-based Compensation (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Share-based Compensation for 10 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 312.57% year-over-year to $3.1 million; the trailing twelve-month figure through Jun 2026 stood at $8.5 million (up 60.82% YoY), and the FY2025 full-year result was $4.3 million, down 47.61% from the prior year.
• Share-based Compensation advanced to $3.1 million in Q2 2026 per XFOR's latest filing, from $2.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $3.1 million in Q2 2026 and bottomed at $519000.0 in Q1 2025.
• Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $1.8 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation sank 70.16% in 2025, then surged 364.93% in 2026.
• Over 5 years, Share-based Compensation stood at $1.1 million in 2022, then soared by 129.36% to $2.5 million in 2023, then fell by 12.68% to $2.2 million in 2024, then gained by 2.44% to $2.3 million in 2025, then surged by 35.89% to $3.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $3.1 million, $2.4 million, and $2.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.